menu ☰
menu ˟

Atezolizumab plus bevacizumab and chemotherapy prolongs PFS in non-small cell lung cancer

07 Dec 2017
The addition of atezolizumab to first-line treatment with bevacizumab and chemotherapy extended PFS by 38% among individuals with advanced nonsquamous non-small cell lung cancer, according to the agent’s manufacturer.Atezolizumab (Tecentriq, Genent...

Click here to view the full article which appeared in Hematology Oncology

IPH Logo